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Background: Carriers of the transmembrane 6 superfamily mem-
ber 2 E167K gene variant (TM6SF2EK/KK) have decreased expres-
sion of the TM6SF2 gene and increased risk of NAFLD and
NASH. Unlike common ‘obese/metabolic’ NAFLD, these subjects
lack hypertriglyceridemia and have lower risk of cardiovascular
disease. In animals, phosphatidylcholine (PC) deficiency results
in a similar phenotype. PCs surround the core of VLDL consisting
of triglycerides (TGs) and cholesteryl-esters (CEs). We deter-
mined the effect of the TM6SF2 E167K on these lipids in the
human liver and serum and on hepatic gene expression and stud-
ied the effect of TM6SF2 knockdown on hepatocyte handling of
these lipids.
Methods: Liver biopsies were taken from subjects characterized
with respect to the TM6SF2 genotype, serum and liver lipidome,
gene expression and histology. In vitro, after TM6SF2 knockdown
in HuH-7 cells, we compared incorporation of different fatty acids
into TGs, CEs, and PCs.
Results: The TM6SF2EK/KK and TM6SF2EE groups had similar age,
gender, BMI and HOMA-IR. Liver TGs and CEs were higher and
liver PCs lower in the TM6SF2EK/KK than the TM6SF2EE group
(p\0.05). Polyunsaturated fatty acids (PUFA) were deficient in
liver and serum TGs and liver PCs but hepatic free fatty acids
were relatively enriched in PUFA (p\0.05). Incorporation of
PUFA into TGs and PCs in TM6SF2 knockdown hepatocytes was
decreased (p\0.05). Hepatic expression of TM6SF2 was
decreased in variant carriers, and was co-expressed with genes
regulated by PUFAs.
Conclusions: Hepatic lipid synthesis from PUFAs is impaired and
could contribute to deficiency in PCs and increased intrahepatic
TG in TM6SF2 E167K variant carriers.
 2017 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Introduction
Common non-alcoholic fatty liver disease (NAFLD) is associated
with features of the metabolic syndrome, such as hypertriglyc-
eridemia, and increased risk of cardiovascular disease (CVD).1 In
2014, a non-synonymous adenine-to-guanine substitution
(rs58542926) replacing glutamate at residue 167 with lysine
(E167K) in the transmembrane 6 superfamily member 2
(TM6SF2) protein was shown to increase liver fat content2,3 and
the risk of liver fibrosis.4 In these and several subsequent studies,
variant allele carriers (TM6SF2EK/KK) were found to be neither
more obese nor more insulin-resistant than non-carriers
(TM6SF2EE).2,5–12 In contrast to most cases with ‘obese/metabolic’
NAFLD, TM6SF2 variant allele carriers have normal5,6,10,11 or
decreased2,8–10,12 plasma TG concentrations and a reduced risk
of CVD.12,13
The exact function of the TM6SF2 variant is unknown. In hep-
atocytes, TM6SF2 minor allele carriage is associated with
decreased TM6SF2 protein expression.2 TM6SF2 siRNA inhibition
in hepatocytes increases cellular TG concentrations and reduces
TG secretion, while overexpression of TM6SF2 has the opposite
effect.3 In mice, hepatic knockdown of TM6SF2 increases liver
triglycerides (TG) and cholesteryl esters (CE), the main con-
stituents of the hydrophobic core of very low-density lipoprotein
(VLDL) particles.2
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Hepatic steatosis, reduced hepatic TG secretion, and protec-
tion from CVD characterize animals with deletion of genes that
are involved in phosphatidylcholine (PC) synthesis such as CTP:
phosphocholine cytidylyltransferase alpha (CTa) and phos-
phatidylethanolamine N-methyltransferase (PEMT).14,15 A similar
phenotype also results from deletion of lysophosphatidylcholine
acyltransferase 3 (LPCAT3), which decreases hepatic concentra-
tions of polyunsaturated PCs.16 PCs are the only phospholipids
required for assembly of VLDL particles.15 PC deficiency increases
intrahepatic degradation of VLDL particles and thereby reduces
their secretion.15 Dietary restriction of choline, a precursor of
PC, increases liver fat in humans.17 Consumption of a
methionine-choline-deficient diet, a widely used in vivo experi-
mental model for NAFLD and NASH, reduces hepatic PC synthesis
and plasma TGs and increases liver TGs without inducing insulin
resistance.15,18 In humans, a polymorphism in PEMT, which
reduces PC synthesis, may be more frequent in participants with
NAFLD19–21 and in participants with non-alcoholic steatohepati-
tis (NASH)22 than in those without, and characterizes participants
who develop NAFLD on a choline-depleted diet.23 Since these
changes resemble those of carriers of the TM6SF2 E167K gene
variant,2–13 we hypothesized that reduced PC synthesis might
characterize carriers of the E167K variant.
In the present study, we profiled hepatic gene expression and
measured concentrations of TGs, CEs, PCs and free fatty acids
(FFA) in human liver biopsy samples from carriers (TM6SF2EK/KK)
and non-carriers (TM6SF2EE) of the TM6SF2 E167K variant. Since
the in vivo results seemed to support our hypothesis, we directly
measured incorporation of saturated (16:0, palmitic acid),
monounsaturated (18:1, oleic acid), and polyunsaturated fatty
acids (20:4, arachidonic acid) into TG, CE, and PC pools in TM6SF2
knockdown HuH-7 cells. In addition, we measured circulating
concentrations and composition of TGs, CEs and PCs in carriers
and non-carriers of the gene variant.
Materials and methods
Study participants
Ninety participants were recruited from a cohort of patients undergoing laparo-
scopic bariatric surgery. Following a phone interview and a separate clinical study
visit (vide infra), participants were eligible if they met the following inclusion
criteria:
a. Age 18 to 75 years.
b. No known acute or chronic disease except for features of the metabolic
syndrome based on medical history, physical examination and standard
laboratory tests (complete blood count, serum creatinine, electrolyte
concentrations).
c. Non-diabetic based on 2 h plasma glucose concentrations (611 mmol/l)
during a 75 g oral glucose tolerance test.
d. Alcohol consumption less than 20 g per day in women and less than 30 g
per day in men.
e. No clinical or biochemical evidence of other liver disease, or clinical signs
or symptoms of inborn errors of metabolism.
f. No use of drugs or toxins influencing liver steatosis.
Elevated liver enzymes (alanine aminotransferase (ALT) and aspartate amino-
transferase (AST)) were not exclusion criteria. Participants with diabetes were
excluded from the present study, as we wished to study the impact of the TM6SF2
genotype at rs58542926 rather than that of insulin resistance/diabetes and anti-
diabetic drugs on the human liver lipidome. The effect of the latter was reported
earlier in a larger (n = 125) group of participants, which included patients with
diabetes.24 The ethics committee of the Hospital District of Helsinki and Uusimaa
approved the study, which was conducted in accordance with the Declaration of
Helsinki. Each participant provided written informed consent after the nature and
potential risks of the study had been fully explained.
Metabolic study
One week prior to surgery, all participants were invited to a clinical visit for meta-
bolic characterization after an overnight fast. Anthropometric measurements
(body weight, height and waist circumference) were taken, an intravenous can-
nula inserted in an antecubital vein and blood collected for measurement of HbA1c,
serum insulin and adiponectin, plasma glucose, LDL- and HDL-cholesterol, triglyc-
eride, AST, ALT, ALP, GGT and albumin concentrations and for genotyping of
PNPLA3 rs738409 and TM6SF2 rs58542926 as previously described.24
The participants underwent an oral glucose (75 g) tolerance test (OGTT).25
HOMA-IR26 and Matsuda insulin sensitivity index27 were used as surrogates for
insulin resistance. Body weight of the participants did not differ between the time
of the metabolic study and surgery (128.9 ± 2.3 and 128.5 ± 2.3 kg; non-
significant [NS]). The participants were divided into groups based on their TM6SF2
rs58542926 genotype (E167K variant allele carriers, TM6SF2EK/KK, n = 10 and non-
carriers, TM6SF2EE, n = 80).
Liver biopsies and liver histology
Routine wedge biopsies of the liver were taken immediately at the beginning of
the surgery. Part of the biopsy was snap-frozen in liquid nitrogen for subsequent
analysis of molecular lipids and gene expression; the other part was sent to an
experienced liver pathologist (J.A.) for blinded analysis of liver histology accord-
ing to the criteria proposed by Brunt et al.28 Liver fat was quantified as the per-
centage of hepatocytes with macrovesicular steatosis.
Hepatic lipidomic and free fatty acid analysis
Hepatic lipidomic analyses of TGs, CEs and PCs were performed using a Q-TOF
Premier (Waters, Milford, MA) quadrupole time-of-flight mass spectrometer com-
bined with an Acquity Ultra Performance liquid chromatograph (LC) (Waters, Mil-
ford, MA). Liquid chromatography methods are described in the Supplementary
material. Hepatic FFAs were analysed using an Agilent 6890 gas chromatograph
equipped with a split/splitless injector (Agilent Technologies, Santa Clara, CA),
cryogenic dual-stage modulator and time-of-flight mass spectrometer (Leco
Corp., St. Joseph, MI, USA) as described in detail in Supplementary material. All
analyses were blinded.
Hepatic RNA sequencing
Since the results (vide infra) suggested that TM6SF2 might be involved in synthe-
sis of polyunsaturated lipids, we examined hepatic gene expression using RNA
sequencing. For this, liver samples were available from 69 of the original cohort.
An additional 25 participants were recruited using the same criteria as the orig-
inal cohort. The characteristics of these participants (n = 94) are shown in
Table S2. The samples were prepared using Illumina TruSeq RNA Sample Prepara-
tion Kit (Illumina, San Diego, CA) and sequencing was performed using a paired-
end 101 base pair protocol on HiSeq2000 platform (Illumina, San Diego, CA). The
methods for RNA sequencing, data processing and pathway analysis are described
in detail in the Supplementary material.
Serum lipidomic analysis
Serum lipidomic analyses of TGs, CEs and PCs were analysed using an ultra-high-
performance liquid chromatography quadrupole time-of-flight mass spectrome-
try (UHPLC-Q-TOF-MS). The UHPLC was a 1290 Infinity system (Agilent Technolo-
gies, Santa Clara, CA) and the mass spectrometer a 6550 iFunnel Q-TOF (Agilent
Technologies, Santa Clara, CA). Details of the sample preparations and data pre-
processing steps are given in Supplementary material.
In vitro experiments
Stably transduced and transiently silenced HuH-7 human hepatoma derived cells
were used as in vitro hepatocyte models. The former was established by transduc-
ing HuH-7 cells with lentiviral particles expressing shRNA against TM6SF2
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(TRCN0000254085, Sigma-Aldrich, St. Louis, MO) and a control non-targeting
shRNA (SHC002V, Sigma-Aldrich), and the latter by using siRNA against TM6SF2
(SI04187946, Qiagen, Hilden, Germany) and a negative control (SI03650318, Qia-
gen) in HuH-7 cells. Silencing efficiency by quantitative polymerase chain reac-
tion, lipid droplet quantification, and incorporation of tritiated fatty acids
([9,10-3H(N)]-palmitic, [9,10-3H(N)]-oleic and [5,6,8,9,11,12,14,15-3H(N)]-
arachidonic acid, PerkinElmer, Waltham, MA) into TGs, PCs and CEs by thin layer
chromatography were analysed as described in detail in Supplementary material.
Statistical analyses
The Kolmogorov-Smirnov test was used to test the normality of continuous
variables. The independent two-sample Student’s t test and Mann-Whitney U
test were used to compare normally and non-normally distributed data, respec-
tively. Normally distributed data were reported in means ± standard error of
means (SEM) while non-normally distributed data were reported as medians
followed by interquartile ranges. Pearson’s v2 test was used to evaluate if the
distribution of categorical variables differed between the groups. Pearson’s cor-
relation coefficients were calculated as a measure of statistical dependence
between two variables after log-transformation if necessary. Statistical analyses
were performed by using R 3.1.1 (http://www.r-project.org/), IBM SPSS Statistics
22.0.0.0 version (IBM, Armonk, NY), and GraphPad Prism 6.0f for Mac OS X
(GraphPad Software, La Jolla, CA). A two-sided p value of less than 0.05 indi-
cated statistical significance.
The median and, after log2-transformation, the mean concentrations of all
lipids were compared between groups based on TM6SF2 genotype. Benjamini-
Hochberg method was used for multiple hypotheses testing.29 Differences in con-
centrations of TGs were illustrated by a heatmap, where the color intensity of
each cell represents the log2-transformed ratio of mean values of an individual
TG in the TM6SF2EK/KK group divided by the mean values in the TM6SF2EE group.
Fold-change of log2-transformed ratio of mean concentrations of lipids between
the groups was visualized with respect to fatty acyl chain length and saturation.
For further details regarding the materials used, please refer to the CTAT
table.
Results
Characteristics of the study groups
Clinical characteristics of the TM6SF2 genotype groups are shown
in Table 1. The groups were similar with respect to age, gender
and BMI but liver fat was 2-fold higher in the TM6SF2EK/KK than
the TM6SF2EE group (Table 1). Histologic liver fat percentage cor-
related with the sum of all liver TGs measured by UHPLC-MS
(r = 0.81, p\0.001).
Fasting, 30 and 120 min glucose and insulin concentrations
during the OGTT (Fig. 1) and the distribution of PNPLA3
rs738409 genotype (Table 1) were comparable between the
TM6SF2 groups. The TM6SF2EK/KK tended to have higher preva-
lence of hepatic fibrosis compared to the TM6SF2EE group (60%
vs. 31%, p = 0.09).
Hepatic TGs
The increase in TGs in the TM6SF2EK/KK when compared to the
TM6SF2EE group was due to an increase in TG species with 48–
54 carbons and 0–3 double bonds, i.e. TGs containing predomi-
nantly saturated and monounsaturated long-chain fatty acids
(Fig. 2). Concentrations of TGs with 58–60 carbons and 6–11 dou-
ble bonds, i.e. TGs containing predominantly polyunsaturated
fatty acids were decreased in the TM6SF2EK/KK when compared
to the TM6SF2EE group (Fig. 2; Fig. S1; Table S1). Consequently,
the fold-change of concentrations of TGs between the groups
was significantly inversely correlated (r = 0.27, p = 0.0033) with
Table 1. Clinical characteristics of the study participants according to the TM6SF2 genotype at rs58542926.
Total TM6SF2EE (n = 80) TM6SF2EK/KK (n = 10)
Age (years) 45.2 ± 0.9 49.1 ± 2.8
Gender (% women) 71.3 70.0
BMI (kg/m2) 45.4 ± 0.7 45.6 ± 1.7
Waist circumference (cm) 128.3 (120.0–140.0) 127.3 (117.4–135.4)
Liver fat (%) 13.8 ± 2.0 27.5 ± 9.5*
Necroinflammatory grade (0/1/2/3) 67/13/0/0 8/2/0/0
Fibrosis stage (0/1/2/3/4) 55/23/2/0/0 4/5/1/0/0
Fibrosis stage[ 0 (%) 31 60 (p = 0.09)
fS-insulin (mU/L) 12.6 (6.9–18.8) 12.8 (7.7–17.7)
fP-glucose (mmol/L) 5.6 ± 0.1 5.7 ± 0.3
HbA1C (%) 5.7 (5.5–6.0) 5.7 (5.5–6.1)
HbA1C (mmol/mol) 39 (37–42) 39 (37–43)
HOMA-IRy 3.4 ± 0.2 3.6 ± 0.7
Matsuda indexyy 55.4 (36.0–104.9) 56.9 (42.2–74.3)
fS-adiponectin (lg/ml) 8.5 ± 0.5 10.1 ± 1.3
fP-total cholesterol (mmol/L) 4.3 ± 0.1 4.2 ± 0.2
fP-triglycerides (mmol/L) 1.24 (0.91–1.69) 1.34 (0.97–1.60)
fP-HDL cholesterol (mmol/L) 1.13 (0.96–1.37) 1.09 (0.96–1.55)
fP-LDL cholesterol (mmol/L) 2.6 ± 0.1 2.5 ± 0.2
P-AST (IU/L) 30 (25–37) 34 (30–41)
P-ALT (IU/L) 32 (24–45) 42 (28–58)
P-ALP (IU/L) 64 ± 2 70 ± 5
P-GGT (U/L) 28 (21–45) 50 (26–66)
P-albumin (g/L) 38.2 ± 0.3 37.9 ± 1.0
B-platelets (x 109/L) 252 ± 6 276 ± 35
PNPLA3 (n, CC/CG/GG) 41/35/4 6/3/1
TM6SF2 (n, CC/CT/TT) 80/0/0 0/9/1***
Data are in n, means ± SEM or median (25th–75th percentile), and statistical tests are Student’s t test, Mann-Whitney U test and Pearson’s v2-test, as appropriate. *p 60.05.
***p 60.001.
y Homeostasis model assessment of insulin resistance was calculated by formula: fS-Insulin x fP-Glucose/22.5 according to Matthews et al.25
yy Matsuda insulin sensitivity index was calculated from insulin and glucose concentrations measured at 0, 30 and 120 min during the oral glucose tolerance test as
proposed by DeFronzo and Matsuda.26
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the number of double bonds in TGs (Fig. S1). In vitro, TM6SF2
knockdown HuH-7 cells had 52% lower TM6SF2mRNA expression
than control HuH-7 cells (p\0.001) (Fig. 3A). Incorporation of
palmitic acid (16:0, a saturated fatty acid) (+117%, p\0.01) and
oleic acid (18:1n-9, a monounsaturated fatty acid) (+39%,
p\0.05) into TGs in the TM6SF2 knockdown HuH-7 cells were
significantly increased, while that of arachidonic acid (20:4n-6,
a polyunsaturated fatty acid) was significantly decreased
(34%, p\0.001) (Fig. 3D). Transient silencing (78%) of TM6SF2
in HuH-7 cells induced similar changes in fatty acid incorporation
into TGs (Fig. S2A).
Hepatic CEs
The concentration of total liver CEs was 20% higher in the
TM6SF2EK/KK than the TM6SF2EE group (p\0.05) (Fig. 4). Among
individual CE species, the concentration of CE(16:0) was signifi-
cantly higher in the TM6SF2EK/KK group than the TM6SF2EE group
(p\0.05), while those of CE(16:1), CE(18:1) and CE(18:2) tended
to increase (p = 0.07, p = 0.06, and p = 0.05, Fig. 4). In TM6SF2
knockdown HuH-7 cells, incorporation of palmitic acid (16:0)
into CE was significantly (+149%, p\0.05) and that of oleic acid
(18:1) almost significantly (+76%, p = 0.06, Fig. 3E) increased.
Transient silencing of TM6SF2 in HuH-7 cells induced similar
changes in fatty acid incorporation into CEs (Fig. S2C).
Hepatic PCs
In the human liver samples, total PCs were significantly lower in
the TM6SF2EK/KK than the TM6SF2EE group (11%, p\0.05; Fig. 4).
The fold-change of PCs between the groups was significantly
inversely correlated with the number of double bonds
(r = 0.40, p\0.001) but not with the number of carbons in
PCs. Thus, polyunsaturated PCs were responsible for the decrease
in total PCs (Fig. 4). To determine whether the decrease in
polyunsaturated PCs was secondary to an increase in liver TG,
we plotted liver TGs against individual polyunsaturated PC con-
centrations. As shown in Fig. S3, for any given liver TG concentra-
tion, those of polyunsaturated PCs were significantly lower in the
TM6SF2EK/KK than the TM6SF2EE group.
In TM6SF2 knockdown HuH-7 cells, the relative incorporation
of arachidonic acid to PC was significantly lower than in control
cells (32%, p\0.05, Fig. 3F), while incorporations of palmitic
(+236%, p\0.001) and oleic (+65%, p\0.05) acids were increased
(Fig. 3D). Transient silencing of TM6SF2 expression in HuH-7 cells
induced similar changes in fatty acid incorporation into PCs
(Fig. S2B).
Hepatic FFA
The concentration of total hepatic FFA was significantly lower in
the TM6SF2EK/KK (700 [595–822] nmol/g) than the TM6SF2EE
group (904 [755–1,098] nmol/g, p\0.01). Among the individual
FFA, concentrations of palmitic (16:0, 286 [254–346] vs. 383
[307–456] nmol/g, p\0.01), stearic (18:0, 131 [125–188] vs.
195 [160–231] nmol/g, p\0.01), oleic (18:1, 140 [131–168] vs.
191 [141–247] nmol/g, p\0.05) and linoleic (18:2, 67 [50–81]
vs. 84 [67–102] nmol/g, p\0.05) acids were significantly lower
in the TM6SF2EK/KK compared to the TM6SF2EE group (Fig. 4).
The relative proportion of arachidonic acid (20:4) in total FFA
was significantly higher (+15%, p\0.05) in the TM6SF2EK/KK com-
pared to the TM6SF2EE group (Fig. 4).
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Serum TGs, PCs and CEs
In the serum, the fold-change of TGs in the TM6SF2EK/KK com-
pared to the TM6SF2EE group tended to inversely correlate with
the number of double bonds (p = 0.07) and number of carbons
(p = 0.07) in TGs (Fig. 5). The intercepts of the fold-change regres-
sion lines between the groups were highly significantly, lower
than 0 in serum TGs and PCs according to number of double
bonds (p\0.0001 for both TGs and PCs) and carbons
(p\0.0001 for both), but not in serum CEs (Fig. 5).
Hepatic gene expression
TM6SF2 mRNA expression was significantly downregulated in
variant allele carriers (number of rs58542926 minor (T) alleles
vs. TM6SF2 expression, b = 0.41 ± 0.11, p\0.001, Fig. S4). In
pathway analyses, three pathways related to lipids, i.e. ‘metabo-
lism of lipids and lipoproteins’, ‘peroxisomal lipid metabolism’
and ‘triglyceride synthesis’, were enriched with genes signifi-
cantly correlated with TM6SF2 (Fig. 6; Table S3). Among individ-
ual genes which were positively co-expressed with TM6SF2 (and
therefore decreased in TM6SF2 E167K carriers) were those associ-
ated with fatty acid (fatty acid synthase [FASN], acetyl-CoA car-
boxylase beta [ACACB]) and triglyceride (diacylglycerol
acyltransferase [DGAT]1, DGAT2) synthesis, and VLDL metabolism
(apolipoprotein C-III [APOC3]), while those which were inversely
co-expressed with TM6SF2 included genes related to fatty acid
oxidation (carnitine palmitoyltransferase 1 [CPT1]), peroxisome
proliferator-activator receptors alpha and gamma (PPARA, PPARG)
and eicosanoid synthesis (arachidonate 5-lipoxygenase [ALOX5])
(Fig. 6).
Discussion
To the best of our knowledge, this is, the first study to compare
human hepatic lipid profiles between carriers and non-carriers
of the TM6SF2 E167K gene variant. Variant allele carriers had sig-
nificantly higher hepatic TGs and CEs but lower total PCs due to a
decrease in polyunsaturated PCs. Polyunsaturated fatty acids
(PUFAs) were also deficient in serum and liver TGs but relatively
enriched in liver FFA (Fig. 7). Consistent with this in vivo finding,
using stably transduced and transiently silenced HuH-7 cells as
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Fig. 3. In vitro experiments. A) TM6SF2 mRNA expression in control shRNA (shNT) and TM6SF2 shRNA (shTM6SF2) expressing HuH-7 cells. The experiment was run twice
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Fig. 4. Differences in hepatic cholesteryl esters (CE), phosphatidylcholines
(PC) and free fatty acids (FFA) between the groups. Concentrations of total and
individual liver CEs (top left panel) and total liver PCs (top right panel) in
TM6SF2EK/KK relative to TM6SF2EE group. The height of the bars represent% lipid
concentration in TM6SF2EK/KK relative to TM6SF2EE group. Linear regression
between the number of double bonds (middle left panel) and carbons (middle
right panel) in PCs and fold-change of liver PCs in the TM6SF2EK/KK vs. the
TM6SF2EE group (solid line). The intercepts and slopes denote deviation of this
regression line from 0. Each circle denotes a different lipid. Concentrations of
different liver FFA (bottom left panel) and liver FFA as a percentage of total
(bottom right panel) in TM6SF2EK/KK and TM6SF2EE. Data are in means ± SEM or
median (25th–75th percentile); Student’s t test and Mann-Whitney U test, as
appropriate; *p\0.05, **p\0.01.
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in vitro hepatocyte models, TM6SF2 knockdown led to reduced
incorporation of PUFAs into PCs and TGs. In the human liver,
TM6SF2was downregulated in variant allele carriers. Thus, down-
regulation of TM6SF2 increases liver TG and CE and decreases PC
content by impairing lipid synthesis from PUFAs.
To examine the effect of the TM6SF2 E167K variant on human
hepatic lipid content and composition, we divided the partici-
pants based on TM6SF2 genotype (TM6SF2EK/KK vs. TM6SF2EE). Car-
riers of this gene variant had 2-fold higher liver fat content but
the groups did not differ with respect to HOMA-IR or insulin or
glucose concentrations during the OGTT, or obesity. PNPLA3
genotype, which influences hepatic lipid composition,24,39 was
also similar between the groups. Lack of features of insulin resis-
tance between carriers and non-carriers of the TM6SF2 allele is
similar to the finding of Kozlitina et al. in three independent
cohorts.2 In keeping with several previous studies involving
300,5 3616 and 6917 participants, there was no difference in fast-
ing plasma triglyceride concentrations between the TM6SF2
genotype groups. However, in larger studies including 7309,
1,20112 and 4,5872 participants, the variant allele has been asso-
ciated with decreased circulating triglycerides. In the present
study, variant allele carriers displayed deficiency of TGs and
PCs in the circulation as compared to non-carriers in serum lipi-
domic analysis (Fig. 5). Deficiency of TGs and PCs in serum in the
face of increased liver TG suggests defective hepatic lipid export,
in line with previous data.2,8–10,12
In the liver of TM6SF2 E167K variant carriers compared to
non-carriers (Fig. 2, Fig. 4; Fig. S1) and in vitro in hepatocytes
(Fig. 3D, F), PUFAs in both PCs and TGs were decreased while
the proportion of polyunsaturated arachidonic acid in total liver
FFA was increased (Fig. 4). These results imply that the TM6SF2
E167K variant may regulate channeling of PUFAs into PC and
TG synthesis. The first step in the incorporation of free PUFAs into
these lipids is activation into a fatty acyl-CoA by an acyl-CoA syn-
thetase (ACS) enzyme.33 The number of ACS enzymes has rapidly
increased and includes at least 26 isoforms.34 These enzymes
vary with respect to their substrate preference and subcellular
localisation, and channel distinct fatty acids into different meta-
bolic pathways.33,34 For example, knockdown of acyl-CoA syn-
thetase long-chain family member 3 (ACSL3), which is
expressed in the liver and intestine and localised in the endoplas-
mic reticulum similarly to TM6SF2, decreases incorporation of
unsaturated fatty acids into PC, causes PC deficiency, and inhibits
secretion of VLDL in HuH-7 cells.35
Regarding the mechanisms by which PC deficiency and excess
polyunsaturated FFA interfere with VLDL metabolism, assembly,
secretion and degradation of VLDL needs to be considered. The
assembly of VLDL has two major steps.36 First, a nascent VLDL
particle is formed in the ER, where it undergoes maturation to
become a relatively lipid-poor small VLDL2 particle.
36 This small
particle is translocated to the Golgi complex and may be secreted
as such, or undergoes a second lipidation step in which more TGs
and CEs are added to the particle to form a highly-lipidated large
VLDL1 particle.
36
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Fig. 5. Fold-change in serum triglycerides (TGs), phosphatidylcholines (PCs)
and cholesteryl esters (CEs) in the TM6SF2EK/KK group compared to the
TM6SF2
EE group. Linear regression between the number of double bonds (left
panels) and carbons (right panels) in serum TGs (top), PCs (middle), and CEs
(bottom) and fold-change of respective serum lipids in the TM6SF2EK/KK vs. the
TM6SF2EE group (solid line). The intercepts and slopes denote deviation of this
regression line from 0. Each circle denotes a different lipid.
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In TM6SF2 knockout mice, large VLDL particles are deficient in
the circulation in the face of an unchanged or increased total
number of particles secreted.37 This was suggested to reflect a
defect during the second lipidation step.37 Consistent with these
data in mice, in humans, large VLDL1 particles are markedly defi-
cient in the circulation in TM6SF2 E167K variant allele carriers
compared to non-carriers.11 This may be caused by PC defi-
ciency15 or excess polyunsaturated FFA.36,40 For example, in iso-
lated mouse hepatocytes, reduced PC synthesis due to knockout
of PEMT increases degradation and decreases secretion of partic-
ularly the highly-lipidated VLDL particles.38 Polyunsaturated FFA
increase VLDL degradation by a similar mechanism.40 Thus, PC
deficiency and the relative increase in polyunsaturated FFA in
TM6SF2 variant carriers might lead to accumulation of TGs and
CEs via degradation of highly-lipidated VLDL, in keeping with
the conclusion of Hobbs and coworkers.37
Hepatic expression of TM6SF2 mRNA was decreased in E167K
variant carriers (Fig. S4). Three lipid-related pathways were
enriched with genes co-expressing with TM6SF2 (Fig. 6). Among
individual genes, expression of those related to lipogenesis and
lipid export (e.g. FASN, ACACB, DGAT2, DGAT1 and APOC3) was
decreased, while expression of genes related to peroxisome
proliferator-activated receptors, mitochondrial fatty acid oxida-
tion, and eicosanoid synthesis (e.g. PPARA, PPARG, CPT1, ALOX5)
was increased in the variant carriers (Fig. 6). Decreased expres-
sion of DGAT1 and DGAT2 in variant carriers is in line with previ-
ous in vitro data.3 Interestingly, virtually identical changes in
these genes are induced by PUFAs,41 in part via transcriptional
regulation by peroxisome proliferator-activated receptors42
(Fig. 6). These findings are consistent with the in vivo and
in vitro data suggesting impaired hepatic incorporation of PUFA
to TGs, CEs and PCs, increased relative concentrations of arachi-
donic acid in hepatic FFA, and deficiency of TGs and PCs in serum
in TM6SF2 E167K gene variant carriers.
Although we observed PC deficiency both in the liver and in
serum in humans carrying the TM6SF2 E167K variant compared
to non-carriers, no changes in hepatic PC concentrations were
observed in TM6SF2 knockout mice.37 This could be due to species
difference. The main finding of the present study, i.e. impaired
hepatic lipid synthesis from PUFAs in TM6SF2 E167K variant car-
riers, however, is entirely compatible with data in TM6SF2 knock-
out mice displaying reduced percentage of 20:4 and 22:6 in total
hepatic lipids.37
Even though the sample size in the present study was large
considering the difficulty in obtaining human liver samples, the
number of variant allele carriers was low given the variant allele
frequency of 7%. The observed differences may thus underesti-
mate true differences between carriers and non-carriers of the
TM6SF2 E167K gene variant. We had no detailed dietary records
of the patients. This is a limitation as PC is also an important diet-
ary component.43 However, it is unlikely that genotype would
affect intake of PC or its subsequent metabolism in gut lumen
by bacteria to biologically active metabolites such as trimethy-
lamine N-oxide.44
In keeping with human data of Liu et al.,4 carriers of the
TM6SF2 E167K variant tended to have increased liver fibrosis
compared to non-carriers (60 vs. 31%, p = 0.09). PC deficiency
and the relative excess of arachidonic acid found in the present
study may contribute to NASH and fibrosis by several mecha-
nisms. PC deficiency induced by a methionine-choline-deficient
diet induces lipid peroxidation, stellate cell activation and fibrosis
in rats.45 Excess arachidonic acid increases lipid peroxidation,
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Fig. 7. Summary of changes in hepatic polyunsaturated fatty acid (PUFA) metabolism in vivo in TM6SF2 E167K gene variant carriers, and in vitro in TM6SF2
knockout HuH-7 cells. The percentage of hepatic free 20:4 fatty acid (FA) is increased in vivo. First step in synthesis of cholesteryl esters (CE), triglycerides (TG), and
phosphatidylcholines (PC) is activation of free fatty acids into acyl-coenzyme A (CoA). These acyl-CoAs are esterified with cholesterol to form CEs. The in vitro incorporation
of 20:4 into CEs is decreased, and concentrations of serum polyunsaturated CE are decreased in vivo. Acyl-CoAs are also utilized in de novo synthesis (via synthesis of
lysophosphatidic acid, phosphatidic acid and diacylglycerol) of TGs and PCs. Incorporation of 20:4 into TGs and PCs is decreased in vitro, and hepatic concentrations of
polyunsaturated TGs and PCs are decreased in vivo. Hepatic gene expression in vivo is characterized by changes in the expression of genes regulated by free PUFA. In
summary, these in vivo and in vitro findings suggest that hepatic lipid synthesis from PUFA is impaired in TM6SF2 E167K gene variant carriers.
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and apoptosis,46 and stellate cell collagen expression in vitro,47
while arachidonic acid deficiency has opposite effects.48 Arachi-
donic acid can be metabolized into proinflammatory
eicosanoids,33 which circulating concentrations are increased in
participants with NASH.49,50 Increased liver fat content per se
may increase the risk of NASH, as evidenced by recent prospec-
tive liver biopsy data.51
In conclusion, hepatic synthesis of polyunsaturated fatty acid-
containing lipids is impaired in TM6SF2 E167K gene variant carri-
ers and leads to deficiency of polyunsaturated PCs and excess
polyunsaturated FFA in the human liver. These changes, based
on abundant experimental data, could impair VLDL lipidation
via increased degradation, and explain the phenotype character-
izing TM6SF2 E167K carriers i.e. hepatic steatosis, lack of circulat-
ing hypertriglyceridemia and an increased risk of NASH.
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